Vor Biopharma (VOR) Other Non-Current Liabilities (2025 - 2026)
Vor Biopharma (VOR) reported Other Non-Current Liabilities of $638.5 million for Q1 2026, up 6.31% quarter-over-quarter from $600.5 million in Q4 2025.
Vor Biopharma (VOR) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 2 years of Other Non-Current Liabilities data on file, last reported at $638.5 million in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $638.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $638.5 million (changed N/A YoY), and the FY2025 annual result was $600.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $638.5 million in Q1 2026 per VOR's latest filing, from $600.5 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $2.4 billion in Q3 2025 and troughed at $600.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Vor Biopharma | 627.54 Mn | 627.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 638.46 Mn |
| Dec 31, 2025 | 600.55 Mn |
| Sep 30, 2025 | 2.38 Bn |
| Jun 30, 2025 | 1.65 Bn |